Log In
Print this Print this

CERC-301, MK-0657

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionSmall molecule NMDA receptor NR2B subtype (GRIN2B; NR2B; GluN2B) antagonist
Molecular Target NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B)
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationDepression
Indication DetailsTreat depression; Treat major depressive disorder (MDD); Treat suicidality
Regulatory Designation

U.S. - Fast Track (Treat major depressive disorder (MDD))


Cerecor Inc.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today